Literature DB >> 9538686

A good antisense molecule is hard to find.

A D Branch1.   

Abstract

Antisense molecules and ribozymes capture the imagination with their promise of rational drug design and exquisite specificity. However, they are far more difficult to produce than was originally anticipated, and their ability to eliminate the function of a single gene has never been proven. Furthermore, a wide variety of unexpected non-antisense effects have come to light. Although some of these side effects will almost certainly have clinical value, they make it hard to produce drugs that act primarily through true antisense mechanisms and complicate the use of antisense compounds as research reagents. To minimize unwanted non-antisense effects, investigators are searching for antisense compounds and ribozymes whose target sites are particularly vulnerable to attack. This is a challenging quest.

Mesh:

Substances:

Year:  1998        PMID: 9538686     DOI: 10.1016/s0968-0004(97)01155-9

Source DB:  PubMed          Journal:  Trends Biochem Sci        ISSN: 0968-0004            Impact factor:   13.807


  26 in total

1.  RNA aptamers as effective protein antagonists in a multicellular organism.

Authors:  H Shi; B E Hoffman; J T Lis
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

2.  "Mutagenesis" by peptide aptamers identifies genetic network members and pathway connections.

Authors:  C R Geyer; A Colman-Lerner; R Brent
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

Review 3.  Recent advances in molecular biological techniques and their relevance to pulmonary research.

Authors:  B W Robinson; D J Erle; D A Jones; S Shapiro; W J Metzger; S M Albelda; W C Parks; A Boylan
Journal:  Thorax       Date:  2000-04       Impact factor: 9.139

4.  Potent and nontoxic antisense oligonucleotides containing locked nucleic acids.

Authors:  C Wahlestedt; P Salmi; L Good; J Kela; T Johnsson; T Hökfelt; C Broberger; F Porreca; J Lai; K Ren; M Ossipov; A Koshkin; N Jakobsen; J Skouv; H Oerum; M H Jacobsen; J Wengel
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

Review 5.  Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides.

Authors:  R L Juliano; S Alahari; H Yoo; R Kole; M Cho
Journal:  Pharm Res       Date:  1999-04       Impact factor: 4.200

6.  Eukaryotic ribonucleases HI and HII generate characteristic hydrolytic patterns on DNA-RNA hybrids: further evidence that mitochondrial RNase H is an RNase HII.

Authors:  F Pileur; J J Toulme; C Cazenave
Journal:  Nucleic Acids Res       Date:  2000-09-15       Impact factor: 16.971

7.  Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression.

Authors:  B M Tyler; K Jansen; D J McCormick; C L Douglas; M Boules; J A Stewart; L Zhao; B Lacy; B Cusack; A Fauq; E Richelson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

8.  Specificity of short interfering RNA determined through gene expression signatures.

Authors:  Dimitri Semizarov; Leigh Frost; Aparna Sarthy; Paul Kroeger; Donald N Halbert; Stephen W Fesik
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-13       Impact factor: 11.205

9.  Artificial neural network prediction of antisense oligodeoxynucleotide activity.

Authors:  Michael C Giddings; Atul A Shah; Sue Freier; John F Atkins; Raymond F Gesteland; Olga V Matveeva
Journal:  Nucleic Acids Res       Date:  2002-10-01       Impact factor: 16.971

10.  Optimization of trans-splicing ribozyme efficiency and specificity by in vivo genetic selection.

Authors:  Brian G Ayre; Uwe Köhler; Robert Turgeon; Jim Haseloff
Journal:  Nucleic Acids Res       Date:  2002-12-15       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.